drugset / Trial / NCT00004441
Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis
Treatment
Summary
OBJECTIVES: I. Determine the optimum dose of tauroursodeoxycholic acid (TUDCA) required to achieve maximal bioavailability for patients with cystic fibrosis-associated liver disease. II. Compare optimized doses of TUDCA with ursodiol (ursodeoxycholic acid; UDCA) for effects on biliary bile acid composition and metabolism, serum biochemistries, fat absorption, and fat-soluble vitamin status in these patients.
Timeline
- Start
- 1997-09
- Primary completion
- —
- Completion
- 2001-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Taurursodiol | Small molecule | — | Oral |
| Subject | Ursodeoxycholic Acid | Small molecule | — | Oral |